ANOGENITAL CANCER--EPIDEMIOLOGY, BIOCHEMISTRY, AND IMMUNOLOGY

这是一项建议，以继续我们的病例对照研究，调查 人乳头瘤病毒在肛门生殖器发育中的作用 癌症。这项研究将主要在以下三个县进行 以人口为基础的癌症覆盖的华盛顿州西部 监视系统(CSS)，这是一个参与 国家监测流行病学和结局计划(SEER) 癌症研究所。(阴茎、子宫颈原位腺癌和 来自另外十个县的阴道癌将被包括在内，以提供 足够的样本量。)所有年龄在18岁至74岁之间的男性和女性 恶性肿瘤将被识别并邀请参与，我们 估计将成功采访以下案例的数量： 浸润性宫颈癌248例，肛门及肛周癌108例 阴道癌164例，阴茎癌48例，阴道癌2例，阴道癌2例，阴道癌2例，阴道癌2例，阴道癌164例，阴茎癌48例，阴道癌2例，阴茎癌2例，阴道癌2例，阴道癌164例，阴道癌48例，阴道癌2例，阴道癌2例，阴道癌2例，阴道癌2例，阴茎癌48例。 宫颈癌96例，阴道癌60例 案例)。符合条件的受试者将是所有确诊为One的个人 在1994年7月至1998年6月的五年期间，这六种癌症中。 将就病例和适当的控制措施的历史进行面谈 性传播疾病，以及其他已知的危险因素 每个特定的站点。手术的组织样本将从 所有病例，并将调查人类乳头瘤病毒证据 分子杂交技术。将采集血液样本用于 所有病例和对照，并分析以前接触过的证据 单纯疱疹病毒2型和目前使用的几种类型的HPV 可用的测试。更多的血清将被冷冻以供将来检测 随着新的和/或更敏感的血清学检测 为人乳头瘤病毒开发。

This is a proposal to continue our case-control studies investigating the role of human papillomaviruses (HPV) in the development of anogenital cancers. The study will be conducted primarily in three counties of Western Washington that are covered by the population-based Cancer Surveillance System (CSS), a tumor registry that participates in the Surveillance Epidemiology and End Results Program (SEER) of the National Cancer Institute. (Penile, adenocarcinoma in situ of the cervix, and vaginal cancers from ten additional counties will be included to provide a sufficient sample size.) All men and women aged 18-74 with one of six malignancies will be identified and invited to participate, and we estimate the following number of cases will be successfully interviewed: invasive cancer of the cervix (248 cases); anal and perianal cancer (108 cases); vulvar cancer (164 cases); penile cancer (48 cases); adenocarcinoma of the cervix (96 cases); and cancer of the vagina (60 cases). Eligible subjects will be all individuals with a diagnosis of one of these six cancers during a five-year period from July 1994 - June 1998. Cases and appropriate controls will be interviewed regarding a history of sexually-transmitted diseases, as well as other known risk factors for each specific site. Tissue specimens from surgery will be obtained from all cases and will be probed for evidence of human papillomavirus using molecular hybridization techniques. Blood samples will be collected for all cases and controls and analyzed for evidence of prior exposure to herpes simplex virus type 2 and for several types of HPV using currently available tests. Additional sera will be frozen for future determination of HPV antibodies as new and/or more sensitive serologic tests are developed for HPV.